0248/2015 - Participação do setor público no fornecimento de medicamentos para dislipidemias em estudo de base populacional Public sector participation in the supply of dyslipidemia medicines in a population-based study
• Airton José Petris - Petris, Airton José - Universidade Estadual de Londrina, Departamento de Saúde Coletiva - <airton.petris@gmail.com> +
Coautor(es):
• Regina Tanno Kazue de Souza - Souza, Regina Tanno Kazue de - Universidade Estadual de Londrina, Departamento de Saúde Coletiva - <reginatano@hotmail.com>
• Maira Sayuri Sakay Bortoletto - Bortoletto, Maira Sayuri Sakay - Universidade Estadual de Londrina, Departamento de Saúde Coletiva - <mairuska@gmail.com>
Área Temática:
Assistência Farmacêutica
Resumo:
A utilização de medicamentos para tratamento das dislipidemias é relevante no controle das doenças cardiovasculares. Objetivo: Analisar a prevalência, a utilização e a participação do setor público no fornecimento de medicamentos para as pessoas a partir de 40 anos em farmacoterapia de controle das dislipidemias, residentes em um município da região Sul do Brasil. Metodologia: Estudo transversal de base populacional. Resultados: Foram entrevistados no domicilio 1180 indivíduos a partir de 40 anos residentes em Cambé/PR, dos quais 967 realizaram exames laboratoriais. A prevalência de dislipidemias foi de 69,2%, dos quais 16,1% utilizavam medicamentos. Entre os indivíduos em tratamento para as dislipidemias 22,2% apresentaram resultados de exames adequados. Os fármacos hipolipemiantes mais utilizados foram sinvastatina (81,5%) e bezafibrato (6,5%), obtidos principalmente por pagamento direto em farmácias e drogarias privadas (52,2%) e serviços próprios do SUS (33,6%). Conclusão: Em nível populacional a prevalência das dislipidemias foi elevada, o seu controle baixo, com menor participação do setor público no fornecimento dos medicamentos do que a aquisição mediante pagamento direto em farmácias e drogarias privadas, sugerindo alcance limitado das políticas públicas de controle das dislipidemias.
The use of medications for the treatment of dyslipidemia is relevant in the control of cardiovascular diseases. Objective: Analyze the prevalence, the use and the participation of the public sector in the supply of medicines for adults aged 40 years or more undergoing pharmacotherapy for dyslipidemia control, residents in a city in Southern Brazil. Methods: Population-based cross-sectional study. Results: Were interviewed in the household in 1180 individuals from 40 years living in Cambé/PR, of whom 967 underwent laboratory examinations, were interviewed in their household. The prevalence of dyslipidemia was 69.2%, 16.1% among whom using drugs. Among individuals in treatment for dyslipidemia, 22.2% had normal test results. Lipid-lowering drugs used were simvastatin (81.5%) and bezafibrate (6.5%), mainly obtained by direct payment to private pharmacies and drug stores (52.2%) and NHS services (33.6%). Conclusion: It was observed a high prevalence of dyslipidemias at the population level, a low level of dyslipidemia control, accompanied by a low participation of the public sector regarding the medicines supplies comparing with the acquisition through direct payment of the medicines in private pharmacies. These results suggest a low scope of the public policies applied to get the dyslipidemia control.
Public sector participation in the supply of dyslipidemia medicines in a population-based study
Resumo (abstract):
The use of medications for the treatment of dyslipidemia is relevant in the control of cardiovascular diseases. Objective: Analyze the prevalence, the use and the participation of the public sector in the supply of medicines for adults aged 40 years or more undergoing pharmacotherapy for dyslipidemia control, residents in a city in Southern Brazil. Methods: Population-based cross-sectional study. Results: Were interviewed in the household in 1180 individuals from 40 years living in Cambé/PR, of whom 967 underwent laboratory examinations, were interviewed in their household. The prevalence of dyslipidemia was 69.2%, 16.1% among whom using drugs. Among individuals in treatment for dyslipidemia, 22.2% had normal test results. Lipid-lowering drugs used were simvastatin (81.5%) and bezafibrate (6.5%), mainly obtained by direct payment to private pharmacies and drug stores (52.2%) and NHS services (33.6%). Conclusion: It was observed a high prevalence of dyslipidemias at the population level, a low level of dyslipidemia control, accompanied by a low participation of the public sector regarding the medicines supplies comparing with the acquisition through direct payment of the medicines in private pharmacies. These results suggest a low scope of the public policies applied to get the dyslipidemia control.
Petris, Airton José, Souza, Regina Tanno Kazue de, Bortoletto, Maira Sayuri Sakay. Participação do setor público no fornecimento de medicamentos para dislipidemias em estudo de base populacional. Cien Saude Colet [periódico na internet] (2015/set). [Citado em 23/12/2024].
Está disponível em: http://cienciaesaudecoletiva.com.br/artigos/participacao-do-setor-publico-no-fornecimento-de-medicamentos-para-dislipidemias-em-estudo-de-base-populacional/15321?id=15321
